



氏名	宋培培	ソウ バイバイ
役職	国立研究開発法人 国立国際医療研究センター 国際医療協力局 グローバルヘルス政策研究センター 上級研究員 Global Health & Medicine 編集室長	
専門分野	・ 医療技術評価 ・ 診断ツールの開発と評価 ・ 医療・健康 ビッグデータの解析と評価	

メッセージ

NCGM 刊行の Global Health & Medicine 学術英文誌の編集を通じて、グローバルヘルス・医療政策などの国際学術研究の推進と発展や、医療の質的向上に貢献します。

略歴

- 2010-2011 東京大学医学部附属病院・肝胆膵外科・客員研究員
2011-2015 東京大学大学院医学系研究科 博士課程外科学専攻 医学博士・学位取得
2015-2018 東京大学大学院新領域創成科学研究科・客員共同研究員
2018-2019 日本大学医学部消化器外科・研究員
2019-現在 国立国際医療研究センター 国際医療協力局
グローバルヘルス政策研究センター 上級研究員；
Global Health & Medicine, Office Director & Executive Editor ;
WHO Collaborating Center for Primary Health Care (Shanghai, China), Special Consultant.

主要論文

2020 年 6 月までに 100 以上の研究に関連する学術論文が掲載・発表

SELECTED PUBLICATIONS (*corresponding author)

1. Wang H, Song P*, Gu Y, Schroeder E, Jin C. Rapid health systems change: online medical consultations to fight COVID-19. *Ann Transl Med.* 2020; 8:726.
2. Song P, Karako T. Scientific solidarity in the face of the COVID-19 pandemic: researchers, publishers, and medical associations. *Global Health & Medicine.* 2020; 2:56-59.
3. Karako K, Song P*, Chen Y, Tang W. Analysis of COVID-19 infection spread in Japan based on stochastic transition model. *BioSci Trends.* 2020; 14:134-138.
4. Song P, Midorikawa Y, Nakayama H, Higaki T, Moriguchi M, Aramaki O, Yamazaki S, Aoki M, Teramoto K, Takayama T. Patients' prognosis of intrahepatic cholangiocarcinoma and

- combined hepatocellular-cholangiocarcinoma after resection. *Cancer Med.* 2019; 8: 5862-5871.
5. Karako K, Chen Y, Song P*, Tang W. Super-aged society: Constructing an integrated information platform of self-recording lifelogs and medical records to support health care in Japan. *BioSci Trends.* 2019; 13:276-278.
 6. Xia J, Rong L, Sawakami T, Inagaki Y, Song P, Hasegawa K, Sakamoto Y, Tang W. Shuang Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma. *Biomed Pharmacother.* 2018; 9:921-930.
 7. Xia JF, Inagaki Y, Wang L, Song P*. Traditional Chinese medicine as complementary medicine in treatment of female infertility. *Chin J Integr Med.* 2017; 23:245-252.
 8. Song P*, Tang Q, Feng X, Tang W. Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma. *Scand J Clin Lab Invest.* 2016; 245:S70-S76.
 9. Song P, Xia J, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. *World J Gastroenterol.* 2016; 22:262-274.
 10. Song P, Inagaki Y, Wang ZG, Hasegawa K, Sakamoto Y, Arita J, Tang W, Kokudo N. High levels of gamma-glutamyl transferase and indocyanine green retention rate at 15 minutes as preoperative predictors of tumor recurrence in patients with hepatocellular carcinoma. *Medicine (Baltimore).* 2015; 94:e810.
 11. Inagaki Y, Song P, Kokudo N, Tang W. New 'multi-omics' approach and its contribution to hepatocellular carcinoma in China. *Chin J Cancer Res.* 2014; 26:639-640.
 12. Song P, Feng X, Inagaki Y, Song T, Zhang K, Wang Z, Zheng S, Ma K, Li Q, Kong D, Wu Q, Zhang T, Zhao X, Hasegawa K, Sugawara Y, Kokudo N, Tang W; Japan-China Joint Team for Medical Research and Cooperation on HCC. Clinical utility of simultaneous measurement of alpha-fetoprotein and des- γ -carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects. *BioSci Trends.* 2014; 8:266-273.
 13. Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China. *Liver Cancer.* 2013; 2:31-39.
 14. Song P, Feng X, Zhang K, Song T, Ma K, Kokudo N, Dong J, Tang W. Perspectives on using des- γ -carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. *Hepatobiliary Surg Nutr.* 2013; 2:227-231.
 15. Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: A comparison of guidelines from 2001 to 2011. *Liver Int.* 2012; 32:1053-1063.
 16. Gao J, Inagaki Y, Song P, Qu X, Kokudo N, Tang W. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. *Pharmacol Res.* 2012; 65:23-30.